Aurora vs Curaleaf: M&A Clash Reaches Shareholder Decision Point

EDMONTON – STAMFORD – Aurora Cannabis Inc. filed its directors’ circular, unanimously urging shareholders to REJECT the unsolicited takeover bid from Curaleaf Holdings Inc., calling the offer inadequate and warning it puts long-term shareholder value at risk. Curaleaf fired back the same afternoon, reaffirming its bid and calling Aurora’s board defiant at shareholders’ expense.

The offer in question values Aurora at US$4.00 per share: 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash. Curaleaf’s math puts the implied premium at 45% over Aurora’s unaffected 30-day volume weighted average price, or 110% on an ex-cash basis, with the total deal valued at roughly $272 million. The bid is capped at US$5.00 per share and expires December 1, 2026.

Aurora Says the Price Is Wrong & the Risk Is Real

Aurora’s board, guided by a special committee of independent directors and outside financial and legal advisers, concluded after a full review that the offer fails on both price and structure. CEO and Executive Chairman Miguel Martin argued that Curaleaf has over $1 billion in debt and would gain control over Aurora’s cash without paying fairly, while Aurora remains debt-free and holds about C$149 million in cash. He warned shareholders that the bid would leave them with subordinate voting shares and limited influence in any combined company.

The board contends that the claimed premium is inflated by Curaleaf’s own framing – an assessment backed, at least partly, by outside voices. TD Securities wrote in August that the bid “undervalues Aurora and does not adequately reflect its medical cannabis leadership, balance sheet flexibility, international expertise or long-term growth potential.”

The core of Aurora’s resistance is its European footprint. The company’s business in Germany holds EU-GMP certified manufacturing capacity and has launched localized digital platforms in Germany, the U.K., and Poland. Aurora holds the No. 1 market share position in Poland and two of its proprietary cultivars rank in the top five by sales in Germany, where Aurora is one of only three active in-country producers holding a production and R&D license. International revenues grew 17% year-over-year. The offer’s hard cap at US$5.00 per share also drew criticism. That ceiling is lower than the price at which Aurora shares traded as recently as December 18, 2025.

Curaleaf: The Time Is Running Out for Aurora

Curaleaf Chairman and CEO Boris Jordan did not mince words in his response. He called Aurora’s continued refusal to engage in meaningful price discussions “disappointing,” saying it shows disregard for the interests of the company’s own shareholders. In Curaleaf’s telling, Aurora’s own forward guidance tells the real story: management’s projections call for fiscal 2027 revenue to return to approximately fiscal 2025 levels, with adjusted EBITDA expected to decline precipitously from fiscal 2026 results.

Curaleaf also challenged the narrative that Aurora’s cash position reflects underlying strength. Aurora’s operating cash flow was negative in the June quarter, and the company has raised approximately $398 million through equity issuances since September 2020, resulting in roughly 31% dilution. Aurora sold shares through its at-the-market program at average prices of $3.57 during fiscal 2026 and $3.09 during the June quarter – both figures below Curaleaf’s current offer price. Curaleaf, by contrast, generated $157 million in operating cash flow over the last twelve months.

Curaleaf’s sharpest line targeted Aurora’s restructuring narrative directly:

“A six-year program is not a transformation. It is the business model. The current CEO was appointed in September 2020, and business transformation costs have been charged in seven consecutive years.”

The two companies also clashed over the record of private talks. Curaleaf says it has not had a single substantive conversation on the deal, and that Aurora refused to engage, refused to sign an NDA, and refused a site visit despite claiming to be open to discussions. Aurora maintains its lead independent director corresponded actively with Curaleaf’s CEO through July 24, 2026, and disputes the portrayal of a one-sided standoff.

The Decision Ahead

To succeed, Curaleaf must secure more than 50% of outstanding Aurora shares, with at least 66.67% of shares on a fully diluted basis – a threshold that becomes significantly harder to clear without board support.

The most clarifying thing Curaleaf did with this bid was confirm [publicly, and in dollar terms] exactly how valuable Aurora’s European infrastructure is. The strategic rationale for a combination is genuine. The price, however, is the part Aurora shareholders will have to reckon with for themselves over the months ahead. When the company pursuing an acquisition openly acknowledges the target’s assets are “highly strategic,” that is the most unvarnished piece of due diligence a shareholder can get.